Library · Metabolic & weight · Treatment of HIV-associated lipodystrophy
Tesamorelin (Egrifta)
TH9507, Egrifta, trans-3-hexenoyl-GHRH(1-44)-NH2
A synthetic GHRH analogue, marketed as Egrifta and FDA-approved to reduce excess abdominal fat in HIV patients with lipodystrophy, by prompting the pituitary to release growth hormone that acts on fat tissue.
Research score 90/100. Reference only, not a dose.
- Fat Loss
- Growth Hormone Release
- Metabolic Enhancement
- Anti-aging
- Gut Health
- Hormone Regulation
- US status
- Prescription Only
- Approval
- FDA Approved
- Evidence
- FDA Approved (Egrifta).
- Research score
- 90 / 100
- Indication
- HIV/AIDS (Entry Inhibitor)
- Origin
- Canada
- Source category
- Digestive System
- Status group
- Approved / prescription
Mechanism
Binds GHRH receptors on pituitary cells to stimulate GH synthesis and release, raising IGF-1 and promoting fat breakdown especially in visceral fat, with structural changes giving it greater stability and half-life than natural GHRH while preserving receptor specificity.
Safety file
Injection-site reactions and hypersensitivity can occur; risk of glucose intolerance or diabetes; raises IGF-1, requiring cancer monitoring.
- Injection site reactions
- Joint pain
- Muscle pain
- Numbness in extremities
- Mild nausea
- Sleep disturbances